Because of you — your signature, your comment, your video, your donation, the GLP-1 Collective nonprofit has taken the next major step in the fight for affordable GLP-1 access.

This month, the GLP-1 Collective submitted a formal letter to the U.S. Food and Drug Administration, and your voice was included.

🔹 Nearly 27,000 petition signatures
🔹 Over 380 public patient comments
🔹 Personal stories and videos
🔹 Community support, visibility, and generosity

All of it was included in the official submission. Together, we’ve built a record that can’t be ignored.

📬 What the FDA Letter Asked
The letter outlines five urgent regulatory actions the FDA could take — including preserving compounded access, fast-tracking generics, expanding affordability programs, and ensuring insurance coverage for GLP-1s as medically necessary care.

We also requested:
🗓️ A formal meeting with the FDA within 30 days
🔍 Greater transparency around the "Demonstrably Difficult to Compound" (DDC) list
📢 Inclusion of patient advocacy organizations in the FDA's decision-making process

🎥 Watch & Read the Full Submission
📹 Watch the full video reading of our letter
📖 Read the letter
📰 Read the full newsletter on LinkedIn + appendices (petition, comments, data, precedent)

The GLP-1 Collective will share updates on the FDA’s response and any next steps, including opportunities for patients and advocates to stay involved.

💖 Thank you for supporting this work, every signature and every voice matters.

Disclaimer: I am sharing this update in my own words. It does not represent or imply the official statements of the GLP-1 Collective. The GLP-1 Collective is a 501(c)(3) nonprofit organization. Donations are tax-deductible where allowed by law. The organization is not currently registered to solicit in all states.